Aprogen Biologics Inc recorded a significant insider purchase on September 23, 2026, involving 12.7 million shares valued at approximately 20 billion KRW. This transaction represents a 2.05% increase in float ownership. Despite a 23.6% decline in stock price over the last ninety days, this singular acquisition remains the only recent activity reported.